The diversity of HIV-1 is a confounding problem for vaccine design, as the human immune response appears to favor poor or strain-specific responses to any given HIV-1 virus strain. A significant portion of this diversity is manifested as sequence variability in the loops of HIV-1's surface envelope glycoprotein. Here we show that the most variable sequence positions in the third variable (V3) loop crown cluster to a small zone on the surface of one face of the V3 loop ß-hairpin conformation. These results provide a novel visualization of the gp120 V3 loop, specifically demonstrating a surprising preponderance of conserved three-dimensional structure in a highly sequence-variable region. From a structural point of view, there appears to be less diversity in this region of the HIV-1 “principle neutralizing domain” than previously appreciated.
Get full access to this article
View all access options for this article.
References
1.
HuangC, TangM, ZhangMet al.Structure of a V3-containing HIV-1 gp120 core. Science, 2005; 310,5750:1025–1028.
2.
Lo ConteL, AileyB, HubbardT, BrennerS, MurzinA, ChothiaC. SCOP: A structural classification of proteins database. Nucleic Acids Res, 2000; 28,1:257–259.
3.
TrkolaA, DragicT, ArthosJet al.CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature, 1996; 384,6605:184–187.
4.
HillC, DengH, UnutmazDet al.Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J Virol, 1997; 71,9:6296–6304.
5.
LeitnerT, FoleyB, HahnBet al.HIV Sequence Compendium. Los Alamos National Laboratory, NM: Theoretical Biology and Biophysics Group, 2005No. LA-UR 06-0680.
6.
BurkeV, WilliamsC, SukumaranMet al.Structural basis of the cross-reactivity of genetically related human anti-HIV-1 monoclonal antibodies: Potential implications for design of V3 based immunogens. Structure, 2009; 17,11:1538–1546.
7.
StanfieldR, GornyM, WilliamsC, Zolla-PaznerS, WilsonI. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure, 2004; 12,2:193–204.
8.
StanfieldR, GornyM, Zolla-PaznerS, WilsonI. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J Virol, 2006; 80,12:6093–6105.
9.
BellC, PantophletR, SchiefnerAet al.Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J Mol Biol, 2008; 375,4:969–978.
10.
DhillonA, StanfieldR, GornyM, WilliamsC, Zolla-PaznerS, WilsonI. Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set. Acta Crystallogr D Biol Crystallogr, 2008; D64,Pt 7:792–802.
11.
PageKA, LandauNR, LittmanDR. Construction and use of a human-immunodeficiency-virus vector for analysis of virus infectivity. J Virol, 1990; 64,11:5270–5276.
12.
ConnorRI, ChenBK, ChoeS, LandauNR. VPR is required for efficient replication of human-immunodeficiency-virus type-1 in mononuclear phagocytes. Virology, 1995; 206,2:935–944.
13.
HeJ, ChoeS, WalkerR, Di MarzioP, MorganD, LandauN. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol, 1995; 69,11:6705–6711.
14.
SmithAJ, ChoMI, HammarskjoldML, RekoshD. Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles. J Virol, 1990; 64,6:2743–2750.
15.
RekoshD, NygrenA, FlodbyP, HammarskjoldML, WigzellH. Coexpression of human immunodeficiency virus envelope proteins and tat from a single simian-virus 40 late replacement vector. Proc Natl Acad Sci USA, 1988; 85,2:334–338.
16.
DeclercqE, YamamotoN, PauwelsRet al.Highly potent and selective-inhibition of human-immunodeficiency-virus by the bicyclam derivative JM3100. AntimicrobAgents Chemother, 1994; 38,4:668–674.
17.
BridgerGJ, SkerljRT, ThorntonDet al.Synthesis and structure-activity-relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication––effects of macrocyclic ring size and substituents on the aromatic linker. J Med Chem, 1995; 38,2:366–378.
18.
HendrixCW, FlexnerC, MacFarlandRTet al.Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother, 2000; 44,6:1667–1673.
19.
BabaM, NishimuraO, KanzakiNet al.A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA, 1999; 96,10:5698–5703.
20.
DragicT, TrkolaA, ThompsonDADet al.A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA, 2000; 97,10:5639–5644.
21.
BjorndalA, DengHK, JanssonMet al.Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol, 1997; 71,10:7478–7487.
22.
JeffsSA, GornyMK, WilliamsCet al.Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120. Immunol Lett, 2001; 79,3:209–213.
23.
GornyMK, ConleyAJ, KarwowskaSet al.Neutralization of diverse human-immunodeficiency-virus type-1 variants by an anti-V3 human monoclonal-antibody, 447-52D. J Virol, 1992; 66,12:7538–7542.
24.
GornyMK, VanCottTC, HioeCet al.Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J Immunol, 1997; 159,10:5114–5122.
25.
GiglerA, DorschS, HemauerAet al.Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol, 1999; 73,3:1974–1979.
26.
NyambiPN, NkengasongJ, PeetersMet al.Reduced capacity of antibodies from patients infected with human-immunodeficiency-virus type-1 (HIV-1) group-O to neutralize primary isolates of HIV-1 group-M viruses. J Infect Dis, 1995; 172,5:1228–1237.
27.
AlmondD, TetsuyaK, KongX, Zolla-PaznerS, CardozoT. Dynamic characterization of the V3 loop crown. Antiviral Ther, 2007; 12,Suppl 4:P13–31.
28.
CardozoT, KimuraT, PhilpottS, WeiserB, BurgerH, Zolla-PaznerS. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses, 2007; 23,3:415–426.
29.
GornyM, WilliamsC, VolskyBet al.Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol, 2002; 76,18:9035–9045.
30.
GornyM, XuJ, KarwowskaS, BuchbinderA, Zolla-PaznerS. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol, 1993; 150,2:635–643.
31.
PantophletR, Aguilar-SinoR, WrinT, CavaciniL, BurtonD. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology, 2007; 364,2:441–453.
32.
Zolla-PaznerS, CohenS, PinterAet al.Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology, 2009; 392,1:82–93.
33.
Zolla-PaznerS, CohenSS, KrachmarovC, WangSX, PinterA, LuS. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology, 2008; 372,2:233–246.
34.
KaurH, RaghavaGPS. An evaluation of beta-turn prediction methods. Bioinformatics, 2002; 18,11:1508–1514.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
